Abstract
The clinical impact of pharmacogenomics in psychiatry has been limited. Part of the problem is the "mismatch" between the precisions of genotyping and the generally weak clinical databases which have been used. It will be unlikely that pharmacogenomics will reach its promise until an inherent industrialization takes place in which high throughput genotyping is applied to controlled, large scale clinical trials. Intramural NIMH double-blind placebo controlled prospective investigation of clozapine in which superiority is demonstrated for clozapine in comparison to typical antipsychotics in both positive and negative symptoms (p
| Original language | English (US) |
|---|---|
| Pages (from-to) | 467 |
| Number of pages | 1 |
| Journal | American Journal of Medical Genetics - Neuropsychiatric Genetics |
| Volume | 96 |
| Issue number | 4 |
| State | Published - Aug 7 2000 |
| Externally published | Yes |
ASJC Scopus subject areas
- Genetics(clinical)
- Neuropsychology and Physiological Psychology
- Neuroscience(all)